After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...